Sugi Predict

Sugi Predict / Compounds / SCHEMBL3623486

SCHEMBL3623486

SCHEMBL3623486

NC(C(=O)O)c1cccc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ HSD17B10 Q99714 5/20 0.50
▸ TDP1 Q9NUW8 4/20 0.50
▸ CYP2C9 P11712 3/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ ACP3 P15309 1/20 0.50
▸ GRM8 O00222 1/20 0.50
▸ GRM6 O15303 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A4 P31645 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ GRM4 Q14833 1/20 0.50
▸ KDM4E B2RXH2 4/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ HPGD P15428 4/20 0.47
▸ GRM1 Q13255 3/20 0.47
▸ GRM2 Q14416 2/20 0.47
▸ PARP1 P09874 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29779063 1.00 MEN1 (0.51) MEN1KMT2AHSD17B10TDP1CYP2C9
SCHEMBL29454480 1.00 MEN1 (0.51) MEN1KMT2AHSD17B10TDP1CYP2C9
SCHEMBL29136047 1.00 MEN1 (0.51) MEN1KMT2AHSD17B10TDP1CYP2C9
SCHEMBL27865867 1.00 MEN1 (0.51) MEN1KMT2AHSD17B10TDP1CYP2C9
Hydrochloric Acid SCHEMBL30049630 0.98 MEN1 (0.50) MEN1KMT2AHSD17B10TDP1CYP2C9
Phenylglycine SCHEMBL28274995 0.91 MEN1 (0.50) MEN1KMT2AHSD17B10TDP1CYP2C9
SCHEMBL1353575 0.85 PARP1 (0.50) MEN1KMT2AACP3PARP1
SCHEMBL1353577 0.85 PARP1 (0.50) MEN1KMT2AACP3PARP1
SCHEMBL3320904 0.82 MEN1 (0.54) MEN1KMT2ATDP1ACP3PARP1
SCHEMBL30057642 0.81 FFAR1 (0.52) MEN1KMT2AHSD17B10TDP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303647-A1 CYCLIC CHEMERIN-9 DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2023-09-28 — — US claimed
EP-4196143-A1 CYCLIC CHEMERIN-9 DERIVATIVES Bayer Aktiengesellschaft (DE) 2023-06-21 — — EP claimed
WO-2022034057-A1 CYCLIC CHEMERIN-9 DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2022-02-17 — — WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US claimed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 — — EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 — — US disclosed
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE ARTHROSI THERAPEUTICS, INC. 2025-07-31 — — US disclosed
EP-4392423-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE Arthrosi Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 — — US disclosed
WO-2023169480-A9 DEUTERATED COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 甘李药业股份有限公司 2024-01-11 — — WO disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 — — CN disclosed
US-20230303647-A1 CYCLIC CHEMERIN-9 DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2023-09-28 — — US disclosed
WO-2001002424-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE DU PONT PHARMACEUTICALS COMPANY (US) 2001-01-11 — — WO disclosed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 — — EP disclosed
EP-0712847-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PEST CONTROL DRUG NIPPON SODA CO., LTD. (JP) 1996-05-22 — — EP disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 — — WO disclosed
EP-0466569-B1 Process for preparation of N-phenylacetyl derivative of tetrahydrothieno[3,2-c]pyridine and intermediate of synthesis SANOFI SA (FR) 1996-04-17 — — EP disclosed
EP-0466569-A1 Process for preparation of N-phenylacetyl derivative of tetrahydrothieno[3,2-c]pyridine and intermediate of synthesis SANOFI (FR) 1992-01-15 — — EP disclosed
US-4297489-A CEPHALOSPORINS BRISTOL-MYERS COMPANY (US) 1981-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 MEN1 537/4885KMT2A 4690/4885HSD17B10 3996/4885
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE EGFR, ABL1, ERBB2 MEN1 1437/4885KMT2A 2421/4885HSD17B10 1856/4885
US-20230303647-A1 CYCLIC CHEMERIN-9 DERIVATIVES CMKLR1, CMKLR2, CCL2 MEN1 1536/4885KMT2A 4544/4885HSD17B10 1631/4885
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 MEN1 537/4885KMT2A 4690/4885HSD17B10 3996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.